Bulletin Du Cancer最新文献

{"title":"Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy","authors":"Yifan Tie ,&nbsp;Jinzhi Xu","doi":"10.1016/j.bulcan.2024.11.009","DOIUrl":"10.1016/j.bulcan.2024.11.009","url":null,"abstract":"<div><h3>Background</h3><div>Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer. Pyroptosis is a programmatic cell death linked to inflammation.</div></div><div><h3>Methods</h3><div>The data information of 541 LUAD samples and 59 normal samples were obtained from TCGA database. The analysis of differentially expressed genes (DEGs) was carried out on LUAD patients. The intersection of integrated PRGs and IRGs with DEGs yielded IPRGs. We utilized univariate Cox regression to determine IPRGs linked to overall survival (OS). Based on their expression levels, unsupervised clustering of LUAD was conducted. Patients were divided into two clusters. Analyses of immunity and drugs were performed in two clusters.</div></div><div><h3>Results</h3><div>One hundred and thirty-two IPRGs were linked with OS. Cluster 1 had a longer OS. Two thousand two hundred and fifty-six DEGs were detected in various subtypes. The results of immune analysis showed that most of the immune cells in cluster 2, which had a worse prognosis, had a low degree of infiltration. High Th2 cell infiltration may be related to poor prognosis in LUAD patients. Higher tumor immune dysfunction and exclusion (TIDE) and immunophenotypic scores in Cluster 1 indicated that these patients may have a better response to immunotherapy. There were significant differences in human leukocyte antigen (HLA), immune checkpoints, immunophenoscore (IPS), and TIDE scores in the two subtypes. The mutation frequencies of the top 10 genes in cluster 2 were higher than those in cluster 1. Different subtypes also had distinct sensitivities to different drugs.</div></div><div><h3>Conclusion</h3><div>IPRGs can be utilized for LUAD subtyping. Different subtypes have varied immune landscapes and immunotherapy responses.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 135-148"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum à l’article « Onco'sport à l’épreuve des patients : expérience vécue des patients atteints d’un cancer pratiquant de l’activité physique adaptée dans le cadre du programme Onco'sport, une étude qualitative » [Bull Cancer 2024;111:587–596]","authors":"Loïc Pages ,&nbsp;Estelle Gouin-Barré ,&nbsp;Céline Bourgier","doi":"10.1016/j.bulcan.2024.12.009","DOIUrl":"10.1016/j.bulcan.2024.12.009","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 236-237"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation de l’expérience des patients en oncologie et pathologies chroniques : analyse critique des outils disponibles (PROMs, PREMs, Satisfaction)","authors":"Loubna Diouri ,&nbsp;Coralie Barbe ,&nbsp;Stéphane Vignot","doi":"10.1016/j.bulcan.2024.11.010","DOIUrl":"10.1016/j.bulcan.2024.11.010","url":null,"abstract":"&lt;div&gt;&lt;div&gt;L’évaluation de la qualité des soins a émergé à la fin des années 1990, conduisant à l’intégration des usagers dans les systèmes de santé. Afin d’intégrer la perception des patients, des ressources existent tels que les PRO (&lt;em&gt;Patient Reported Outcomes&lt;/em&gt;), les PROMs (&lt;em&gt;Patient-Reported Outcome Measures&lt;/em&gt;), la satisfaction et les patients experts ou partenaires. Les PREMs (&lt;em&gt;Patient-Reported Experience Measures)&lt;/em&gt; ont récemment émergé, apportant un regard nouveau pour l’amélioration de la qualité et des parcours de soins mais ils sont encore méconnus. L’objectif de cette étude est de réaliser une analyse critique des publications disponibles sur les outils d’évaluation de l’expérience vécue par le patient, dans son parcours de soins, pour une pathologie chronique avec un focus en oncologie et d’identifier les thèmes communs. Une recherche documentaire a été réalisée de juin 2023 à mars 2024. Elle s’est articulée autour des concepts de qualité de vie, de satisfaction et d’expérience vécue par le patient. Soixante-dix-neuf articles en lien avec l’expérience patient ont été identifiés dont 44 en oncologie et 35 hors oncologie. Les mesures analysées comprennent des questions d’expérience mais aussi des questions de satisfaction et/ou de mesures de PROMs. Néanmoins, elles s’adressent à des domaines concordants qui sont importants pour le patient. Cette étude a permis de constater un développement construit des PROMs et de la satisfaction des patients. Les PREMs et le recueil d’expérience patient sont encore nouveaux. Leurs utilisations restent centrées sur des étapes ciblées de prise en charge et les outils manquent pour évaluer le parcours plus globalement.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Care quality assessment emerged in the late 1990s, leading to the integration of users into healthcare systems. To integrate patient perceptions, resources such as PROs (Patient Reported Outcomes), PROMs (Patient-Reported Outcome Measures), satisfaction and patient experts or partners have been developed. PREMs (Patient-Reported Experience Measures) have recently emerged, bringing a fresh perspective to improving quality and care pathways, but are still little-known. The aim of this study is to carry out a critical analysis of available publications on tools for evaluating the patient's experience of the care pathway for a chronic disease, with a focus on oncology, and to identify common themes. A literature search was carried out from June 2023 to March 2024. It focused on the concepts of quality of life, satisfaction and patient experience. Seventy-nine articles related to patient experience were identified, including 44 in oncology and 35 outside oncology. The measures analyzed include experience questions as well as satisfaction questions and/or PROMs measures. Nevertheless, they address concordant domains that are important to the patient. This study has shown a consistent development of PROMs and patient satisfaction. PROMs and patient experience ","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 178-188"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims database","authors":"Christos Chouaid ,&nbsp;Clarisse Marchal ,&nbsp;Marion Apert ,&nbsp;Lionel Bensimon ,&nbsp;Valérie Guimard ,&nbsp;Mélanie Née ,&nbsp;Manon Belhassen ,&nbsp;Gérard de Pouvourville ,&nbsp;Jean-Yves Blay","doi":"10.1016/j.bulcan.2024.12.007","DOIUrl":"10.1016/j.bulcan.2024.12.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Treatment landscape in metastatic lung cancer has progressed quickly over the last decade, mainly due to immunotherapies and targeted therapies. This study aimed to describe change in epidemiological data of patients with metastatic lung cancer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A cohort of patients identified between 2013 and 2021 with lung cancer and a marker of metastases (ICD-10 code or reimbursement for Bevacizumab or Pemetrexed) was built from the French claims database. A trend analysis of the rate of newly-diagnosed metastatic patients and the proportion of deaths over the study period was performed using Joinpoint® software.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Between 2013 and 2021, 147,760 metastatic lung cancer patients were identified (men: 66.5%, median age: 66 years). A statistically significant decrease in the crude rate of newly-diagnosed metastatic patients was observed in men (−1.18% per year in average), whereas a statistically significant increase was described in women (+2.36% per year in average). A downward trend in the proportion of deaths was found for both gender (−4.37% and −5.07% per year on average, respectively).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;This study provides unpublished epidemiological data on metastatic lung cancer in France and confirms sex-differentiated trends in the rate of newly-diagnosed metastatic patients, already observed for all stages combined. A statistically significant decrease in the proportion of deaths among metastatic lung cancer patients is observed in both genders. These results underline the importance of ongoing investments in prevention and screening initiatives to reverse the incidence trends observed in women. Moreover, it highlights the criticality of therapeutic innovation in sustaining the increase in survival.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;L’offre thérapeutique dans le cancer du poumon métastatique a progressé rapidement ces dix dernières années, principalement grace aux immunothérapies et thérapies ciblées. Cette étude visait à décrire l’évolution des données épidémiologiques des patients avec un cancer du poumon métastatique.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthode&lt;/h3&gt;&lt;div&gt;Une cohorte de patients avec un cancer du poumon et un marqueur de métastases (code CIM-10 ou remboursement de bévacizumab ou pémétrexed) entre 2013 et 2021 a été constituée avec les données de remboursements françaises. Un test de tendance du taux de patients nouvellement diagnostiqués métastatique et de la proportion de décès a été réalisé avec le logiciel Joinpoint®.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Parmi les patients, 147 760 atteints de cancer du poumon métastatique ont été identifiés (hommes : 66,5 %, âge médian : 66 ans). Une diminution statistiquement significative du taux de patients nouvellement diagnostiqués métastatique chez les hommes (−1,18 % par an en moyenne) et une augmentation statistiquement significative chez les femmes (+2,36 % par an en moy","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 166-177"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insuffisance rénale aiguë chez les patients traités par inhibiteur du check-point immunitaire-recommandations communes FITC/SFNDT","authors":"Victor Gueutin ,&nbsp;Stéphane Dalle ,&nbsp;Corinne Isnard-Bagnis ,&nbsp;Ariane Laparra ,&nbsp;Souad Assad ,&nbsp;Stéphane Burtey ,&nbsp;Vincent Audard ,&nbsp;Julie Belliere","doi":"10.1016/j.bulcan.2024.11.001","DOIUrl":"10.1016/j.bulcan.2024.11.001","url":null,"abstract":"<div><div>Les traitements des cancers ont été bouleversés par l’arrivée et le développement des inhibiteurs du <em>check-point</em> (points de contrôle) immunologique (ICI). Ces traitements induisent de multiples effets secondaires dont des insuffisances rénales aiguës. L’association à d’autres traitements rend la réflexion diagnostique complexe. Pour aider les médecins prenant en charge ces patients, la Société française d’immunothérapie du cancer (FITC) et la Société française de néphrologie dialyse et transplantation (SFNDT) proposent des recommandations de prise en charge décrivant le bilan pré-thérapeutique, le diagnostic des différentes atteintes observées et la prise en charge des néphrites interstitielles aiguës secondaires aux ICI. L’essor de l’onconéphrologie, pour laquelle la collaboration entre prescripteurs d’ICI et néphrologues est cruciale, permet d’améliorer les connaissances et l’identification de parcours de prise en charge. Les éléments clés de la réflexion diagnostique sont présentés. La place de la biopsie rénale est revalorisée puisque paraissant peu utilisée par rapport aux bénéfices attendus. Sa réalisation permet de ne pas arrêter à tort l’ICI et d’utiliser les traitements immunosuppresseurs appropriés. Le traitement basé sur la corticothérapie est recommandé selon des schémas dépendant de la sévérité et de la réponse rénale à la corticothérapie. Les traitements alternatifs en cas de résistance à la corticothérapie sont évoqués mais il existe encore peu de données dans les atteintes rénales. La ré-exposition à l’ICI est en général encouragée au vu du faible risque de rechute.</div></div><div><div>Cancer treatments have been dramatically modified by the introduction and the development of immunological checkpoint inhibitors (ICI). These treatments have many side effects, including acute kidney injury (AKI). Their combination with other treatments makes the diagnosis complex. To provide guidance to physicians treating these patients, the FITC and the SFNDT have developed a set of management guidelines covering pre-treatment assessment, diagnosis of the different types of damage observed, and management of acute interstitial nephritis secondary to ICI. Collaboration between oncologists and nephrologists is mandatory. The development of onconephrology is helping to improve knowledge and identify treatment pathways. The key elements of the diagnostic process are presented. The role of renal biopsy is discussed, as it appears to be underused in relation to the expected benefits. Renal biopsy allows ICI to be continued if AKI is not related to AKI. Treatment based on glucocorticoid therapy is recommended, with regimens depending on the severity of the disease and the renal response to glucocorticoid therapy. Alternative treatments for patients resistant to corticosteroids are discussed, but strong data are lacking. Rechallenge should be discussed since it seems to be associated with a good renal prognosis.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 225-235"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Un commentaire : nouvelles sondes ciblées sur l’anhydrase carbonique IX pour l’imagerie des tumeurs hypoxiques","authors":"Diana Igorevna Salnikova ,&nbsp;Andrey Egorovich Shchekotikhin ,&nbsp;Alexander Mikhailovich Scherbakov","doi":"10.1016/j.bulcan.2024.11.006","DOIUrl":"10.1016/j.bulcan.2024.11.006","url":null,"abstract":"<div><div>En 2023, les revues « <em>Bioconjugate Chemistry</em> » et « <em>Sensors and Actuators B: Chemical</em> » ont publié deux articles décrivant de nouveaux biosenseurs pour l’imagerie des régions hypoxiques dans les tumeurs. Cao et al. ont associé de l’acétazolamide (AZA) afin de cibler l’anhydrase carbonique IX (AC IX) à deux chélates de Mn(II)-acide éthylènediaminetétraacétique dérivés de la tyrosine (TyEDTA), sur une structure rigide de triazine (TA). L’objectif de cette synthèse était de créer une sonde d’imagerie par résonance magnétique à base de Mn(II) nommée AZA-TA-Mn. Dans un modèle murin d’hypoxie du carcinome épidermoïde de l’œsophage, l’AZA-TA-Mn, à une faible dose de 0,05<!--> <!-->mmol/kg, a produit un renforcement sélectif du contraste par rapport à l’acide Gd-diéthylénétriaminepentaacétique non spécifique (0,1<!--> <!-->mmol/kg). Une étude de compétition portant sur la co-injection d’AZA libre et de sonde d’imagerie moléculaire par résonance magnétique à base de Mn(II) a confirmé la sélectivité tumorale in vivo de l’AZA-TA-Mn. La coloration par immunofluorescence de coupes de tissus a confirmé la corrélation positive entre l’accumulation tumorale d’AZA-TA-Mn et la surexpression de l’AC IX. En utilisant l’AC IX comme biomarqueur de l’hypoxie, Cao et al. ont donc illustré une stratégie pratique pour le développement de nouvelles sondes d’imagerie pour les régions spécifiques d’hypoxie dans une tumeur d’intérêt.</div></div><div><div>In 2023, the journals “Bioconjugate Chemistry” and “Sensors and Actuators B: Chemical” published two papers describing new biosensors for imaging hypoxic regions in tumors. Cao et al. combined acetazolamide (AZA) to target carbonic anhydrase IX (CA IX) with two tyrosine-derived Mn(II)-ethylenediaminetetraacetic acid chelates (TyEDTA) on a rigid triazine (TA) scaffold. The aim of this synthesis was to create a Mn(II)-based magnetic resonance imaging probe named AZA-TA-Mn. In a murine hypoxia model of esophageal squamous cell carcinoma, AZA-TA-Mn, at a low dose of 0.05<!--> <!-->mmol/kg, produced selective contrast enhancement over non-specific Gd-diethylenetriaminepentaacetic acid (0.1<!--> <!-->mmol/kg). A competition study involving the co-injection of free AZA and a Mn(II)-based magnetic resonance imaging probe confirmed the in vivo tumor selectivity of AZA-TA-Mn. Immunofluorescence staining of tissue sections confirmed the positive correlation between tumor accumulation of AZA-TA-Mn and overexpression of AC IX. Using CA IX as a biomarker of hypoxia, Cao et al. have thus illustrated a practical strategy for the development of novel imaging probes for specific regions of hypoxia in a tumor of interest.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 117-121"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between HPV-16 integration status and cervical intraepithelial neoplasia and cervical cancer in patients infected with HIV","authors":"Peizhi Wang ,&nbsp;Lin Chen ,&nbsp;Huizi Xi ,&nbsp;Baojun Yang ,&nbsp;Peiyi Liang ,&nbsp;Lianhua Tang ,&nbsp;Lijie Yang ,&nbsp;Bin Long ,&nbsp;Huang Huang","doi":"10.1016/j.bulcan.2024.11.005","DOIUrl":"10.1016/j.bulcan.2024.11.005","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to explore the mechanism by which HIV infection promotes cervical cancer and precancerous lesions.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study including 96 patients with high-risk HPV-16 infection who underwent cervical biopsy, cervical conization, or hysterectomy. Among them, 43 patients were diagnosed with both HIV and cervical cancer or precancerous lesions. High-risk HPV infection (HPV16+) positive samples were collected, and total RNA was extracted and amplified by fluorescence quantitative PCR. The expression of HPV E2 and E6 in cervical tissues of HIV-infected and non-HIV-infected patients with high-risk HPV was determined.</div></div><div><h3>Results</h3><div>As the degree of cervical tissue lesions increased, the proportions of integrated HPV-16 increased significantly within both HIV-negative (<em>P</em> <!-->=<!--> <!-->0.008) and HIV-positive groups (<em>P</em> <!-->=<!--> <!-->0.027). In comparison to the HIV-positive group, although the HIV-negative group had a higher proportion of free type HPV-16 infection (64.3% vs. 35.7%) and a lower proportion of integrated type infection (41.7% vs. 58.3%), the differences were not statistically significant (<em>P</em> <!-->=<!--> <!-->0.117). The lower the CD4+ T lymphocyte level, the greater the possibility of HPV-16 integrated infection.</div></div><div><h3>Conclusions</h3><div>Patients with HIV and HPV-16 infection exhibit a significantly higher rate of integrated HPV-16 infection, which is closely linked to HIV-induced immunosuppression, particularly the depletion of CD4+ T lymphocytes. This integration accelerates the progression of cervical lesions, increasing the risk of developing high-grade cervical intraepithelial neoplasia or cervical cancer. These findings underscore the need for targeted screening and therapeutic strategies in HIV-positive women to prevent HPV-related malignancies.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 157-165"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luspatercept en première ligne dans les syndromes myélodysplasiques transfuso-dépendants de risque très faible à intermédiaire","authors":"Urbain Tauveron-Jalenques ,&nbsp;Gaspar Aspas Requena","doi":"10.1016/j.bulcan.2024.11.011","DOIUrl":"10.1016/j.bulcan.2024.11.011","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 113-114"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peginterferon alfa-2a en monothérapie dans la thrombocytémie essentielle","authors":"Yaquine Mechelfekh ,&nbsp;Gaspar Aspas Requena","doi":"10.1016/j.bulcan.2024.11.012","DOIUrl":"10.1016/j.bulcan.2024.11.012","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 115-116"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Santé sexuelle en cancérologie : regards croisés entre bénéficiaires et professionnels d’une association de patients","authors":"Agnès Douvrel ,&nbsp;Xavier Fenouil ,&nbsp;Stéphanie Testu ,&nbsp;Eva Guillot ,&nbsp;Guillaume Buiret ,&nbsp;Claire Combe","doi":"10.1016/j.bulcan.2024.11.007","DOIUrl":"10.1016/j.bulcan.2024.11.007","url":null,"abstract":"<div><div>La santé sexuelle est un aspect central du bien-être et de la qualité de vie des patients atteints de cancer. À travers deux enquêtes distinctes, l’une réalisée auprès des patients et l’autre auprès des professionnels, nous avons évalué les besoins et les pratiques liés à la santé sexuelle en cancérologie. Les résultats révèlent que l’importance accordée à la prise en compte de la vie intime et sexuelle était plutôt élevée mais que le sujet avait été abordé pour 44 % avec un professionnel et majoritairement à leur initiative. Les types d’accompagnement sollicités étaient une consultation dédiée (38 %), et des échanges avec d’autres personnes atteintes de cancer (21 %). Plus de la moitié des professionnels n’abordait pas dans sa pratique la santé sexuelle avec les bénéficiaires. Les besoins recensés étaient une formation spécifique, des temps d’échange et de partage d’expériences avec d’autres professionnels et des ressources (documentations, sites internet de référence). La formation des professionnels, et des outils adaptés semblent nécessaires pour répondre aux attentes des patients.</div></div><div><div>Sexual health is a central aspect of the well-being and quality of life of cancer patients. Through two separate surveys, one conducted among patients and the other among professionals, we assessed the needs and practices relating to sexual health in cancer care. The results showed that the importance attached to taking intimate and sexual life into account was fairly high, but that 44% of patients had discussed the subject with a professional, and the majority had done so on their own initiative. The types of support requested were a dedicated consultation (38%) and exchanges with other people with cancer (21%). More than half of the professionals did not discuss sexual health with their patients. The needs identified were specific training, time to exchange and share experiences with other professionals, and resources (documentation, reference websites). Professional training and appropriate tools seem necessary to meet patients’ expectations.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 199-207"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}